Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.31 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | NR2E3 | Q9Y5X4 | 2/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640192 | 1.00 | KMT2A (0.39) | KMT2AALOX12NPSR1TDP1PPARG | |
| SCHEMBL13640193 | 0.84 | KMT2A (0.37) | KMT2A | |
| SCHEMBL15354843 | 0.82 | KMT2A (0.35) | KMT2A | |
| SCHEMBL13640343 | 0.76 | GAA (0.46) | — | |
| SCHEMBL15354849 | 0.76 | GAA (0.46) | — | |
| SCHEMBL13640171 | 0.72 | KMT2A (0.50) | KMT2AALOX12NPSR1ALDH1A1 | |
| SCHEMBL7457973 | 0.71 | KMT2A (0.36) | KMT2ATDP1ALDH1A1 | |
| SCHEMBL13640164 | 0.69 | KMT2A (0.43) | KMT2AALOX12NPSR1 | |
| SCHEMBL16229721 | 0.67 | KMT2A (0.44) | KMT2AALOX12NPSR1ALDH1A1 | |
| SCHEMBL10410305 | 0.67 | KMT2A (0.44) | KMT2AALOX12NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8568814-B2 | Lanthionine derivatives | AJINOMOTO CO., INC. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-20120282386-A1 | LANTHIONINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282386-A1 | LANTHIONINE DERIVATIVES | CASR, KCNJ5, CALCR | KMT2A 1148/4885ALOX12 2735/4885NPSR1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.